Skip to content
Research/Metabolic Glp1/Cagrilintide

Cagrilintide

compound

preliminary evidencePublic

Long-acting amylin analog; activates AMYR and CTR. In Phase III development. Being combined with semaglutide (CagriSema) in trials showing up to 22-25% weight loss at 32 weeks.

Category: Metabolic Glp1·Updated 5/19/2026
OverviewScienceClinicalSafetyPapersProtocolsOutcomes

Cagrilintide

Long-acting amylin analog; activates AMYR and CTR. In Phase III development. Being combined with semaglutide (CagriSema) in trials showing up to 22-25% weight loss at 32 weeks.

ScienceComing soon
ClinicalComing soon
SafetyComing soon
PapersComing soon
ProtocolsComing soon
OutcomesComing soon